The Fly

Baxter sees some recessionary risk in 2023

Says hospital capital environment in 2023 an "important variable" for the company. Says dimensions "somewhat limited" as far as company’s ability to raise prices until contracts expire at the end of 2024. Says can’t raise prices to offset higher costs until end of 2024. Says close to being in position to submit new pump to FDA, which is an "important variable" for 2023. Comments taken from Evercore ISI Healthconx Conference.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BAX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More